Plasma haemoxygenase-1 in coronary artery disease: A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 1029-1037

  Idriss, Naglaa K ^a   Lip, Gregory Y H ^a   Balakrishnan, Balu ^a   Jaumdally, Rumi ^a   Boos, Christopher J ^a   Blann, Andrew D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Angiogenin; Coronary artery disease; Haemoxygenase 1; Matrix metalloproteinase 9; Tissue inhibitor of metalloproteinase; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIN; BIOLOGICAL MARKER; GELATINASE B; HEME OXYGENASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; AORTA ROOT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY SINUS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL ARTERY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE; UMBILICAL VEIN;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELLS, CULTURED; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEME OXYGENASE-1; HUMANS; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RIBONUCLEASE, PANCREATIC; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149473943     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-11-0802     Document Type: Article

References (43)

1. Tousoulis D, Davies G, Stefanadis C, et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993-997.
2. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47 (8 Suppl): C7-12.
3. Barguer AC, Beeuwes R 3rd, Lainey LL, et al. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-177.
4. Tayebjee MH, Lip GY, Blann AD, et al. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 2005; 115: 205-210.
5. Khurana R, Simons M, Martin JF, et al. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005; 112: 1813-1824.
6. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-429.
7. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99: 1726-1732.
8. Heeschen C, Dimmeler S, Hamm CW, et al.; CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107: 524-530.
9. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355-2360.
10. Kishimoto K, Liu S, Tsuji T, et al. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005; 24: 445-446.
11. Tello-Montoliu A, Marín F, Patel J, et al. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J 2007; 28: 3006-3011.
12. Ponka P. Cell biology of heme. Am J Med Sci 1999; 318: 241-256.
13. Morita T. Hemeoxygenase and atherosclerosis. Arterscler Thromb Vasc Biol 2005; 25: 1786-1808.
14. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79-127. Erratum in: Pharmacol Rev 2008; 60: 242.
15. Deramaudt BM, Braunstein S, Remy P, et al. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 1998; 68: 121-127.
16. Jozkowicz A, Huk I, Nigisch, et al. Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin- IX. Antioxid Redox Signal 2003; 5: 155-162.
17. Bussolati B, Ahmed A, Pemberton H, et al. Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood 2004; 103: 761-766.
18. Fernandez M, Bonkovsky HL. Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. Br J Pharmacol 2003; 139: 634-640.
19. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. Circulation 2007; 116: 2634-2653
20. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra large von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
21. Altman DG. Practical statistics for Medical Research. Chapman and Hall, London, 1991: pp. 219-220.
22. Ishikawa K, Sugawara D, Wang XP, et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in LDL-receptor knockout mice. Circ Rec 2001; 88: 506-512.
23. Idriss NK, Blann AD, Lip GY. Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol 2008; 52: 971-978.
24. Morsi WG, Shaker OG, Ismail EF, et al. HO-1 and VEGF gene expression in human arteries with advanced atherosclerosis. Clin Biochem 2006; 39: 1057-1062.
25. Jazwa A, Loboda A, Golda S, et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006; 40: 1250-1263.
26. Lüblinghoff N, Winkler K, Winkelmann BR, et al. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med Genet 2009; 10: 36-42.
27. Yachie A, Niida Y, Wada T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999: 103; 129-135.
28. Kirino Y, Takeno M, Murakami S, et al. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis Rheum 2007; 56: 464-475.
29. Kinderlerer AR, Pombo Gregoire I, Hamdulay SS, et al. Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin. Blood 2009; 113: 1598-1607
30. Chen SM, Li YG, Wang DM. Study on changes of heme oxygenase-1 expression in patients with coronary heart disease. Clin Cardiol 2005; 28: 197-201.
31. Chen SM, Li YG, Wang DM, et al. Expression of heme oxygenase-1, hypoxia inducible factor-1 alpha, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease. Clin Chem Lab Med 2009; 47: 327-333.
32. Brydun A, Watari Y, Yamamoto Y, et al. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res 2007; 30: 341-348.
33. Devey L, Ferenbach D, Mohr E, et al. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther 2009; 17: 65-72.
34. Stark M, Zubareb J, Jacovovitz R, et al. HO-1 and VEGF gene expressions are time dependent during exposure to welding fumes. Cytokine 2009; 46: 290-295.
35. Cheng C, Noordeloos AM, Jeney V, et al. Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation 2009; 119: 3017-3027.
36. Bussolati B, Mason JC. Dual role of VEGF-induced heme-oxygenase-1 in angiogenesis. Antioxid Redox Signal 2006; 8: 1153-1163.
37. Dulak J, Deshane J, Jozkowicz A, et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology. Focus on angiogenesis. Circulation 2008; 117: 231-241.
38. Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 5: 2537-2546.
39. Loboda A, Jazwa A, Jozkowicz A, et al. Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect hemeoxygenase- 1 in human microvascular endothelials cells. Atherosclerosis 2006; 187: 26-30.
40. Grosser N, Erdmann K, Hemmerle A, et al. Rosuvastatin upregulates the antioxidant defence protein Heme oxygenase-1. Biochem Biophys Res Commun 2004; 325: 871-876.
41. Lee Ts, Chang CC, Zhu Y, et al. Simvastastin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004; 110: 1296-1302.
42. Kronke G, Kadl A, Ikonomu E, et al. Expression of heme oxygenase-1 in human vascular endothelial cells is regulated by peroxisome proliferator- activated receptors. Arterioscl Thromb Vasc Biol 2007; 27: 1276-1282.
43. Grochot-Przeczek A, Dulak J, Jozkowicz A. Haemoxygenase-1 in neovascularisation: A diabetic perspective. Thromb Haemost 2010; 104: 424-431.